Postibrutinib relapse outcomes for patients with marginal zone lymphoma.
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan XC, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Oh TS, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G.
Epperla N, et al. Among authors: kandarpa m.
Blood Adv. 2023 Jan 10;7(1):88-91. doi: 10.1182/bloodadvances.2022008634.
Blood Adv. 2023.
PMID: 36269847
Free PMC article.
No abstract available.